Unlocking healthcare potential for patients
Leveraging our expertise to address unmet medical needs
Our Strategy
Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas.
Mereo BioPharma plans to build a rare and orphan disease commercial business based on products acquired from major pharmaceutical companies.
our products
Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from Astra Zeneca, for the treatment of diseases with considerable unmet medical need.
Each of these programmes has a comprehensive dataset for both pre-clinical and initial phase 2 clinical studies.
Phase 1
Phase 2a
Phase 2b
Phase 3
BPS-804 (SETRUSUMAB)
Osteogenesis Imperfecta (OI)AZD-9668 (ALVELESTAT)
Alpha-1 Antitrypsin DeficiencyBGS-649 (LEFLUTROZOLE)
Hypogonadotropic Hypogonadism (HH) in Obese MenBCT-197 (acumapimod)
Acute Exacerbations of COPDInvestors
Share Price
View Share Price ChartNews
- 22 May 2018 Notice of AGM
- 26 Apr 2018 Update on Offering & Application to List on Nasdaq
- 09 Apr 2018 Mereo BioPharma Announces Launch of Global Offering and Application to List on NASDAQ
Events and conferences
- 18 May 2018 AETHER Phase 2 clinical trial data to be presented at the American Thoracic Society meeting in San Diego, 18 to 23 May
- 26 Sep 2017 Mereo BioPharma to present at the Cantor Global Healthcare Conference in New York, 25-27 September 2017
- 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017